



HU000025138T2

(19) **HU**(11) Lajstromszám: **E 025 138**(13) **T2****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA

- (21) Magyar ügyszám: **E 09 759895**
- (22) A bejelentés napja: **2009. 11. 24.**
- (96) Az európai bejelentés bejelentési száma:
EP 20090759895
- (97) Az európai bejelentés közzétételi adatai:
EP 2367815 A1 **2010. 07. 01.**
- (97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2367815 B1 **2015. 01. 14.**
- (51) Int. Cl.: **C07D 403/08** (2006.01)
A61K 315/06 (2006.01)
A61K 3153/77 (2006.01)
C07D 405/14 (2006.01)
C07D 453/02 (2006.01)
C07D 403/14 (2006.01)
A61P 35/00 (2006.01)
- (86) A nemzetközi (PCT) bejelentési szám:
PCT/EP 09/008360
- (87) A nemzetközi közzétételi szám:
WO 10072296

(30) Elsőbbségi adatok: 102008062826 2008. 12. 23. DE	(73) Jogosult(ak): Merck Patent GmbH, 64293 Darmstadt (DE)
(72) Feltaláló(k): STIEBER, Frank, 69121 Heidelberg (DE) SCHADT, Oliver, 63517 Rodenbach (DE) DORSCH, Dieter, 64372 Ober-Ramstadt (DE) BLAUKAT, Andree, 69198 Schriesheim (DE)	(74) Képvisező: Schläfer László, DANUBIA Szabadalmi és Jogi Iroda Kft., Budapest

(54) **Piridazinon származékok**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

BACKGROUND OF THE INVENTION

The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.

The present invention relates to compounds and to the use of compounds in which the inhibition, regulation and/or modulation of signal transduction by kinases, in particular tyrosine kinases and/or serine/threonine kinases, plays a role, furthermore to pharmaceutical compositions which comprise these compounds, and to the use of the compounds for the treatment of kinase-induced diseases.

In particular, the present invention relates to compounds and to the use of compounds in which the inhibition, regulation and/or modulation of signal transduction by Met kinase plays a role.

One of the principal mechanisms by which cellular regulation is effected is through the transduction of extracellular signals across the membrane that in turn modulate biochemical pathways within the cell. Protein phosphorylation represents one course by which intracellular signals are propagated from molecule to molecule resulting finally in a cellular response. These signal transduction cascades are highly regulated and often overlap, as is evident from the existence of many protein kinases as well as phosphatases. Phosphorylation of proteins occurs predominantly at serine, threonine or tyrosine residues, and protein kinases have therefore been classified by their specificity of phosphorylation site, i.e. serine/threonine kinases and tyrosine kinases. Since phosphorylation is such a ubiquitous process within cells and since cellular phenotypes are largely influenced by the activity of these pathways, it is currently believed that a number of disease states and/or diseases are attributable to either aberrant activation or functional mutations in the molecular components of kinase cascades. Consequently, considerable attention has been devoted to the characterisation of these proteins and compounds that are able to modulate their activity (for a review see: Weinstein-Oppenheim et al. *Pharma. & Therap.*, 2000, 88, 229-279).

The role of the receptor tyrosine kinase Met in human oncogenesis and the possibility of inhibition of HGF (hepatocyte growth factor)dependent Met activation

are described by S. Berthou et al. in *Oncogene*, Vol. 23, No. 31, pages 5387-5393 (2004). The inhibitor SU11274 described therein, a pyrrole-indoline compound, is potentially suitable for combating cancer.

Another Met kinase inhibitor for cancer therapy is described by J.G. Christensen et al. in *Cancer Res.* 2003, 63(21), 7345-55.

Another tyrosine kinase inhibitor for combating cancer is reported by H. Hov et al. in *Clinical Cancer Research* Vol. 10, 6686-6694 (2004). The compound PHA-665752, an indole derivative, is directed against the HGF receptor c-Met. It is furthermore reported therein that HGF and Met make a considerable contribution to the malignant process of various forms of cancer, such as, for example, multiple myeloma.

The synthesis of small compounds which specifically inhibit, regulate and/or modulate signal transduction by tyrosine kinases and/or serine/threonine kinases, in particular Met kinase, is therefore desirable and an aim of the present invention.

It has been found that the compounds according to the invention and salts thereof have very valuable pharmacological properties while being well tolerated.

Specifically, the present invention relates to individual compounds according to Claim 1 covered by the formula I which inhibit, regulate and/or modulate signal transduction by Met kinase, to compositions which comprise these compounds, and to processes for the use thereof for the treatment of Met kinase-induced diseases and complaints, such as angiogenesis, cancer, tumour formation, growth and propagation, arteriosclerosis, ocular diseases, such as age-induced macular degeneration, choroidal neovascularisation and diabetic retinopathy, inflammatory diseases, arthritis, thrombosis, fibrosis, glomerulonephritis, neuro-degeneration, psoriasis, restenosis, wound healing, transplant rejection, metabolic diseases and diseases of the immune system, also autoimmune diseases, cirrhosis, diabetes and diseases of the blood vessels, also instability and permeability and the like in mammals.

Solid tumours, in particular fast-growing tumours, can be treated with Met kinase inhibitors. These solid tumours include monocytic leukaemia, brain, urogenital, lymphatic system, stomach, laryngeal and lung carcinoma, including lung adenocarcinoma and small-cell lung carcinoma.

The present invention is directed to processes for the regulation, modulation or inhibition of Met kinase for the prevention and/or treatment of diseases in connection with unregulated or disturbed Met kinase activity. In particular, the claimed compounds of the formula I according to Claim 1 can also be employed in the treatment of certain forms of cancer. Furthermore, the claimed compounds of the formula I according to Claim 1 can be used to provide additive or synergistic effects in certain existing cancer chemotherapies, and/or can be used to restore the efficacy of certain existing cancer chemotherapies and radiotherapies.

Furthermore, the claimed compounds of the formula I according to Claim 1 can be used for the isolation and investigation of the activity or expression of Met kinase. In addition, they are particularly suitable for use in diagnostic methods for diseases in connection with unregulated or disturbed Met kinase activity.

It can be shown that the compounds according to the invention have an antiproliferative action *in vivo* in a xenotransplant tumour model. The compounds according to the invention are administered to a patient having a hyperproliferative disease, for example to inhibit tumour growth, to reduce inflammation associated with a lymphoproliferative disease, to inhibit transplant rejection or neurological damage due to tissue repair, etc. The present compounds are suitable for prophylactic or therapeutic purposes. As used herein, the term "treatment" is used to refer to both prevention of diseases and treatment of pre-existing conditions. The prevention of proliferation is achieved by administration of the compounds according to the invention prior to the development of overt disease, for example to prevent the growth of tumours, prevent metastatic growth, diminish restenosis associated with cardiovascular surgery, etc. Alternatively, the compounds are used for the treatment of ongoing diseases by stabilising or improving the clinical symptoms of the patient.

The host or patient can belong to any mammalian species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for treatment of human disease.

The susceptibility of a particular cell to treatment with the compounds according to the invention can be determined by *in vitro* tests. Typically, a culture of the cell is combined with a compound according to the invention at various concentrations

for a period of time which is sufficient to allow the active agents to induce cell death or to inhibit migration, usually between about one hour and one week. In vitro testing can be carried out using cultivated cells from a biopsy sample. The viable cells remaining after the treatment are then counted.

The dose varies depending on the specific compound used, the specific disease, the patient status, etc. A therapeutic dose is typically sufficient considerably to reduce the undesired cell population in the target tissue while the viability of the patient is maintained. The treatment is generally continued until a considerable reduction has occurred, for example an at least about 50% reduction in the cell burden, and may be continued until essentially no more undesired cells are detected in the body.

For identification of a signal transduction pathway and for detection of interactions between various signal transduction pathways, various scientists have developed suitable models or model systems, for example cell culture models (for example Khwaja et al., *EMBO*, 1997, 16, 2783-93) and models of transgenic animals (for example White et al., *Oncogene*, 2001, 20, 7064-7072). For the determination of certain stages in the signal transduction cascade, interacting compounds can be utilised in order to modulate the signal (for example Stephens et al., *Biochemical J.*, 2000, 351, 95-105). The compounds according to the invention can also be used as reagents for testing kinase-dependent signal transduction pathways in animals and/or cell culture models or in the clinical diseases mentioned in this application.

Measurement of the kinase activity is a technique which is well known to the person skilled in the art. Generic test systems for the determination of the kinase activity using substrates, for example histone (for example Alessi et al., *FEBS Lett.* 1996, 399, 3, pages 333-338) or the basic myelin protein, are described in the literature (for example Campos-González, R. and Glenney, Jr., J.R. 1992, *J. Biol. Chem.* 267, page 14535).

For the identification of kinase inhibitors, various assay systems are available. In scintillation proximity assay (Sorg et al., *J. of Biomolecular Screening*, 2002, 7, 11-19) and flashplate assay, the radioactive phosphorylation of a protein or peptide as substrate with γ ATP is measured. In the presence of an inhibitory compound, a decreased radioactive signal, or none at all, is detectable.

Furthermore, homogeneous time-resolved fluorescence resonance energy transfer (HTR-FRET) and fluorescence polarisation (FP) technologies are suitable as assay methods (Sills et al., J. of Biomolecular Screening, 2002, 191-214).

Other non-radioactive ELISA assay methods use specific phospho-antibodies (phospho-ABs). The phospho-AB binds only the phosphorylated substrate. This binding can be detected by chemiluminescence using a second peroxidase-conjugated anti-sheep antibody (Ross et al., 2002, Biochem. J.).

There are many diseases associated with deregulation of cellular proliferation and cell death (apoptosis). The conditions of interest include, but are not limited to, the following. The compounds according to the invention are suitable for the treatment of various conditions where there is proliferation and/or migration of smooth muscle cells and/or inflammatory cells into the intimal layer of a vessel, resulting in restricted blood flow through that vessel, for example in the case of neointimal occlusive lesions. Occlusive graft vascular diseases of interest include atherosclerosis, coronary vascular disease after grafting, vein graft stenosis, perianastomatic prosthetic restenosis, restenosis after angioplasty or stent placement, and the like.

PRIOR ART

Other pyridazine derivatives are described as MET kinase inhibitors in WO 2007/065518.

Thiadiazinones are described in DE19604388, WO2003/037349 WO2007/057093 and WO2007/057092.

Dihydropyridazinones for combating cancer are described in WO 03/037349 A1.

Other pyridazines for the treatment of diseases of the immune system, ischaemic and inflammatory diseases are known from EP 1 043 317 A1 and EP 1 061 077 A1.

EP 0 738 716 A2 and EP 0 711 759 B1 describe other dihydropyridazinones and pyridazinones as fungicides and insecticides.


Other pyridazinones are described as cardiogenic agents in US 4,397,854.

JP 57-95964 discloses other pyridazinones.

Other MET kinase inhibitors are described in WO 2008/145243.

SUMMARY OF THE INVENTION

The invention relates to individual compounds according to Claim 1 covered by the formula I






in which

R¹ denotes Ar, Het, A, OR², O[C(R²)₂]_nAr, O[C(R²)₂]_nHet, N(R²)₂, NR²[C(R²)₂]_nAr or NR²[C(R²)₂]_nHet,

R² denotes H or A',

R³, R^{3'} each, independently of one another, denote H, Hal, A, OR², CN, COOR², CON(R²)₂, NR²COA, NR²SO₂A, SO₂N(R²)₂ or S(O)_mA,

Y denotes [C(R²)₂]_nNR²COZ, [C(R²)₂]_nNR²COHet¹, [C(R²)₂]_nCyc[C(R²)₂]_nN(R²)₂, [C(R²)₂]_nCyc[C(R²)₂]_nOR², [C(R²)₂]_nCyc[C(R²)₂]_nHet¹,



[C(R²)₂]_nHet², [C(R²)₂]_nCR²(NR²)₂COOR²,

[C(R²)₂]_nNR²CO[C(R²)₂]_nNR²COA,

[C(R²)₂]_nNR²COOA, [C(R²)₂]_nCO-NR²-A,

[C(R²)₂]_nCO-NR²-[C(R²)₂]_nHet¹, [C(R²)₂]_nCONH₂, [C(R²)₂]_nCONHA,

[C(R²)₂]_nCONA₂, [C(R²)₂]_nCO-NR²-[C(R²)₂]_nN(R²)₂ or COOA,

Z denotes OR²(NR²)₂CR²(OR²)A,

- Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, $[C(R^2)_{2n}]_nOR^2$, $[C(R^2)_{2n}]_nN(R^2)_2$, SR^2 , NO_2 , CN, $COOR^2$, $CON(R^2)_2$, NR^2COA , NR^2SO_2A , $SO_2N(R^2)_2$, $S(O)_m A$, CO-Het, Het, $O[C(R^2)_{2n}]_nN(R^2)_2$, $O[C(R^2)_{2n}]_nHet$, $NHCOOA$, $NHCON(R^2)_2$, $NHCOO[C(R^2)_{2n}]_nN(R^2)_2$, $NHCOO[C(R^2)_{2n}]_nHet$, $NHCONH[C(R^2)_{2n}]_nN(R^2)_2$, $NHCONH[C(R^2)_{2n}]_nHet$, $OCONH[C(R^2)_{2n}]_nN(R^2)_2$, $OCONH[C(R^2)_{2n}]_nHet$, $CONR^2[C(R^2)_{2n}]_nN(R^2)_2$, $CONR^2[C(R^2)_{2n}]_nHet$ and/or COA,
- Het denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, $[C(R^2)_{2n}]_nOR^2$, $[C(R^2)_{2n}]_nN(R^2)_2$, SR^2 , NO_2 , CN, $COOR^2$, $CON(R^2)_2$, NR^2COA , NR^2SO_2A , $SO_2N(R^2)_2$, $S(O)_m A$, CO-Het¹, $[C(R^2)_{2n}]_nHet^1$, $O[C(R^2)_{2n}]_nN(R^2)_2$, $O[C(R^2)_{2n}]_nHet^1$, $NHCOOA$, $NHCON(R^2)_2$, $NHCOO[C(R^2)_{2n}]_nN(R^2)_2$, $NHCOO[C(R^2)_{2n}]_nHet^1$, $NHCONH[C(R^2)_{2n}]_nN(R^2)_2$, $NHCONH[C(R^2)_{2n}]_nHet^1$, $OCONH[C(R^2)_{2n}]_nN(R^2)_2$, $OCONH[C(R^2)_{2n}]_nHet^1$, CO-Het¹, CHO, COA, =S, =NH, =NA and/or =O (carbonyl oxygen),
- Het¹ denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be mono- or disubstituted by A, OA, OH, COOH, COOA, $[C(R^2)_{2n}]_nCyc$, Hal and/or =O (carbonyl oxygen),
- Het² denotes 2-methoxycarbonylpyrrolidin-4-yl, 2-carboxypyrrolidin-4-yl, 1-cyclopropylmethylpiperidin-4-yl, piperidin-4-yl, morpholin-2- or 4-yl, 1-isopropylpiperidin-4-yl, 1-methylpiperidin-4-yl, 4-piperazinyl, 1-methylpyrrolidin-2-yl, 1-tert-butoxycarbonyl-piperidin-4-yl, 1-ethylpiperidin-2-yl, 1-(2-methoxyethyl)piperidin-4-yl, 1-[2-(N,N-dimethylamino)ethyl]piperidin-4-yl, 1,2,2,6,6-pentamethylpiperidin-4-yl, 1-azabicyclo[2.2.2]oct-3-yl, tetrahydropyran-4-yl, 1-formylpiperidin-4-yl or 1-methyl-1-oxy-piperidin-4-yl,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or in which one or two non-adjacent CH₂ groups may be replaced by O, NH, S, SO, SO₂ and/or by CH=CH groups,
- or

	cyclic alkyl having 3-7 C atoms,
A'	denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F,
Cyc	denotes cycloalkylene having 3-7 C atoms,
Hal	denotes F, Cl, Br or I,
m	denotes 0, 1 or 2,
n	denotes 0, 1, 2, 3 or 4,
p	denotes 1, 2, 3, 4 or 5,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

The claimed compounds of the formula I according to Claim 1 are also taken to mean the hydrates and solvates of these compounds, furthermore pharmaceutically usable salts.

The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. Solvates of the compounds are taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.

The expression "effective amount" means the amount of a medicament or of a pharmaceutical active compound which causes in a tissue, system, animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician.

In addition, the expression "therapeutically effective amount" means an amount which, compared with a corresponding subject who has not received this amount, has the following consequence:

improved treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side-effects or also the reduction in the advance of a disease, complaint or disorder.


The term "therapeutically effective amount" also encompasses the amounts which are effective for enhancing normal physiological function.

The invention also relates to the use of mixtures of the claimed compounds of the formula I according to Claim 1, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.

These are particularly preferably mixtures of stereoisomeric compounds.


The invention relates to the compounds of the formula I according to Claim 1 and salts thereof and to a process for the preparation of compounds of the formula I according to Claims 1-10 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, characterised in that

a) a compound of the formula II



in which R¹ has the corresponding meaning in Claim 1,

is reacted with a compound of the formula III



in which Y, R², R³ and R^{3'} have the meanings indicated in Claim 1 and

L denotes Cl, Br, I or a free or reactively functionally modified OH group,

or

b) a radical Y is converted into another radical Y

by

i) acylating or alkylating an amino group,

ii) etherifying a hydroxyl group,

or

c) in that they are liberated from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent,

and/or

a base or acid of the formula I is converted into one of its salts.

The compounds of the formula I according to Claim 1 may have one or more chiral centres and can therefore occur in various stereoisomeric forms. The formula I encompasses all these forms.

The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants known per se which are not mentioned here in greater detail.

The starting compounds of the formulae II and III are generally known. If they are novel, however, they can be prepared by methods known per se.

The pyridazinones of the formula II used are, if not commercially available, generally prepared by the method of W. J. Coates, A. McKillop, Synthesis, 1993, 334-342.

Compounds of the formula I can preferably be obtained by reacting a compound of the formula II with a compound of the formula III.

In the compounds of the formula III, L preferably denotes Cl, Br, I or a free or reactively modified OH group, such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).

The reaction is generally carried out in the presence of an acid-binding agent, preferably an organic base, such as DIPEA, triethylamine, dimethylaniline, pyridine or quinoline.

The addition of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals, preferably of potassium, sodium, calcium or caesium, may also be favourable.

Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30° and 140°, normally between -10° and 90°, in particular between about 0° and about 70°.

Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents.

Particular preference is given to acetonitrile, dichloromethane and/or DMF.

The reaction of a compound of the formula II with a compound of the formula III in which L denotes OH is preferably carried out in a Mitsunobu reaction by addition of, for example, triphenylphosphine and a dialkyl azodicarboxylate. The solvent is preferably THF.

The compounds of the formula I according to Claim 1 can furthermore be obtained by converting a radical R² into another radical R² by, for example, arylating a heterocycle in a Suzuki reaction.

The compounds of the formula I according to Claim 1 can furthermore be obtained by liberating them from their functional derivatives by solvolysis, in particular hydrolysis, or by hydrogenolysis.

Preferred starting materials for the solvolysis or hydrogenolysis are those which contain corresponding protected amino and/or hydroxyl groups instead of one or more free amino and/or hydroxyl groups, preferably those which carry an amino-protecting group instead of an H atom bonded to an N atom, for example those which conform to the formula I, but contain an NHR' group (in which R' is an amino-protecting group, for example BOC or CBZ) instead of an NH₂ group.

Preference is furthermore given to starting materials which carry a hydroxyl-protecting group instead of the H atom of a hydroxyl group, for example those which conform to the formula I, but contain an R¹O-phenyl group (in which R¹ is a hydroxyl-protecting group) instead of a hydroxyphenyl group.

It is also possible for a plurality of - identical or different - protected amino and/or hydroxyl groups to be present in the molecule of the starting material. If the protecting groups present are different from one another, they can in many cases be cleaved off selectively.

The term "amino-protecting group" is known in general terms and relates to groups which are suitable for protecting (blocking) an amino group against chemical reactions, but are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino-protecting groups are removed after the desired reaction (or reaction sequence), their type and size are furthermore not crucial; however, preference is given to those having 1-20, in particular 1-8, carbon atoms. The term "acyl group" is to be understood in the broadest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and, in particular, alkoxycarbonyl, aryloxy carbonyl and especially aralkoxycarbonyl groups. Examples of such acyl groups are alkanoyl, such as acetyl, propionyl and butyryl; aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl and tolyl; aryloxyalkanoyl, such as POA; alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC and 2-iodoethoxycarbonyl; aralkoxycarbonyl, such as CBZ ("carbobenzoxy"), 4-methoxybenzyloxycarbonyl and FMOC; and arylsulfonyl, such as Mtr, Pbf and Pmc. Preferred amino-protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.

The term "hydroxyl-protecting group" is likewise known in general terms and relates to groups which are suitable for protecting a hydroxyl group against chemical reactions, but are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the above-mentioned unsubstituted or substituted aryl, aralkyl or acyl groups, furthermore also alkyl groups. The nature and size of the hydroxyl-protecting groups are not crucial since they are removed again after the desired chemical

reaction or reaction sequence; preference is given to groups having 1-20, in particular 1-10, carbon atoms. Examples of hydroxyl-protecting groups are, inter alia, tert-butoxycarbonyl, benzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, where benzyl and tert-butyl are particularly preferred. The COOH groups in aspartic acid and glutamic acid are preferably protected in the form of their tert-butyl esters (for example Asp(OBut)).

The compounds of the formula I are liberated from their functional derivatives – depending on the protecting group used – for example using strong acids, advantageously using TFA or perchloric acid, but also using other strong inorganic acids, such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids, such as trichloroacetic acid, or sulfonic acids, such as benzene- or p-toluenesulfonic acid. The presence of an additional inert solvent is possible, but is not always necessary. Suitable inert solvents are preferably organic, for example carboxylic acids, such as acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as DMF, halogenated hydrocarbons, such as dichloromethane, furthermore also alcohols, such as methanol, ethanol or isopropanol, and water. Mixtures of the above-mentioned solvents are furthermore suitable. TFA is preferably used in excess without addition of a further solvent, and perchloric acid is preferably used in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9:1. The reaction temperatures for the cleavage are advantageously between about 0 and about 50°, preferably between 15 and 30° (room temperature).

The BOC, OBut, Pbf, Pmc and Mtr groups can, for example, preferably be cleaved off using TFA in dichloromethane or using approximately 3 to 5N HCl in dioxane at 15-30°, and the FMOC group can be cleaved off using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30°.

The trityl group is employed to protect the amino acids histidine, asparagine, glutamine and cysteine. They are cleaved off, depending on the desired end product, using TFA / 10% thiophenol, with the trityl group being cleaved off from all the said amino acids; on use of TFA / anisole or TFA / thioanisole, only the trityl group of His, Asn and Gln is cleaved off, whereas it remains on the Cys side chain.

The Pbf (pentamethylbenzofuranyl) group is employed to protect Arg. It is cleaved off using, for example, TFA in dichloromethane.

Hydrogenolytically removable protecting groups (for example CBZ or benzyl) can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble-metal catalyst, such as palladium, advantageously on a support, such as carbon). Suitable solvents here are those indicated above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF. The hydrogenolysis is generally carried out at temperatures between about 0 and 100° and pressures between about 1 and 200 bar, preferably at 20-30° and 1-10 bar. Hydrogenolysis of the CBZ group succeeds well, for example, on 5 to 10% Pd/C in methanol or using ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-30°.

Pharmaceutical salts and other forms

The said compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared by conventional methods. If the compound of the formula I contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. The aluminium salts of the compounds of the formula I are likewise included. In the case of certain compounds of the formula I, acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate

and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction.

Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(III), iron(II), lithium, magnesium, manganese(III), manganese(II), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-mentioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chlorprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropyl-

amine and tris(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction.

Compounds of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C₁-C₄)alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(C₁-C₄)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C₁₀-C₁₈)alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl(C₁-C₄)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds according to the invention can be prepared using such salts.

The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to represent a restriction.

Particular preference is given to hydrochloride, dihydrochloride, hydrobromide, maleate, mesylate, phosphate, sulfate and succinate.

The acid-addition salts of basic compounds of the formula I are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.

As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.

If a compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.

With regard to that stated above, it can be seen that the expression "pharmaceutically acceptable salt" in the present connection is taken to mean an active compound which comprises a compound of the formula I in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active compound compared with the free form of the active compound or any other salt form of the active compound used earlier. The pharmaceutically acceptable salt form of the active compound can also provide this active compound for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active compound with respect to its therapeutic efficacy in the body.

The invention furthermore relates to medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active compound per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention,

depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active compound per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active compound. Furthermore, pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art.

Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active compound with the excipient(s) or adjuvant(s).

Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.

Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar,

calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medicament after the capsule has been taken.

In addition, if desired or necessary, suitable binders, lubricants and disintegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acacia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape, which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.

Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.

The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.

The compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.

The compounds of the formula I and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyranes, polycyanoacrylates and crosslinked or amphiphatic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active compound can be delivered from the plaster by iontophoresis, as described in general terms in *Pharmaceutical Research*, 3(6), 318 (1986).

Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or cream. In the case of formulation to give an ointment, the active compound can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active compound can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.

Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active compound is dissolved or suspended in a suitable carrier, in particular an aqueous solvent.

Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.

Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.

Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.

Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insufflators.

Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary. Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.

It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours.

A therapeutically effective amount of a compound of the formula I depends on a number of factors, including, for example, the age and weight of the animal, the precise condition that requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. However, an effective amount of a compound according to the invention for the treatment of neoplastic growth, for example colon or breast carcinoma, is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention *per se*. It can be assumed

that similar doses are suitable for the treatment of other conditions mentioned above.

The invention furthermore relates to medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active compound.

The invention also relates to a set (kit) consisting of separate packs of

- (a) an effective amount of a compound of the formula I according to Claim 1 and/or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,
and
- (b) an effective amount of a further medicament active compound.

The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules, each containing an effective amount of a compound of the formula I and/or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,

and an effective amount of a further medicament active compound in dissolved or lyophilised form.

USE

The present compounds are suitable as pharmaceutical active compounds for mammals, especially for humans, in the treatment of tyrosine kinase-induced diseases. These diseases include the proliferation of tumour cells, pathological neovascularisation (or angiogenesis) which promotes the growth of solid tumours, ocular neovascularisation (diabetic retinopathy, age-induced macular degeneration and the like) and inflammation (psoriasis, rheumatoid arthritis and the like).

The present invention encompasses the use of the compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of cancer.

Preferred carcinomas for the treatment originate from the group cerebral carcinoma, urogenital tract carcinoma, carcinoma of the lymphatic system, stomach carcinoma, laryngeal carcinoma and lung carcinoma. A further group of preferred forms of cancer are monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.

Also encompassed is the use of the compounds according to the invention according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of a disease in which angiogenesis is implicated.

Such a disease in which angiogenesis is implicated is an ocular disease, such as retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and the like.

The use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of inflammatory diseases also falls within the scope of the present invention. Examples of such inflammatory diseases include rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reaction and the like.

Also encompassed is the use of the compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of a tyrosine kinase-induced disease or a tyrosine kinase-induced condition in a mammal, in which to this method a therapeutically effective amount of a compound according to the invention is administered to a sick mammal in need of such treatment. The therapeutic amount varies according to the specific disease and can be determined by the person skilled in the art without undue effort.

The present invention also encompasses the use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of retinal vascularisation.

Methods for the treatment or prevention of ocular diseases, such as diabetic retinopathy and age-induced macular degeneration, are likewise part of the invention. The use for the treatment or prevention of inflammatory diseases, such

as rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reaction, as well as the treatment or prevention of bone pathologies from the group osteosarcoma, osteoarthritis and rickets, likewise falls within the scope of the present invention.

The expression "tyrosine kinase-induced diseases or conditions" refers to pathological conditions that depend on the activity of one or more tyrosine kinases. Tyrosine kinases either directly or indirectly participate in the signal transduction pathways of a variety of cellular activities, including proliferation, adhesion and migration and differentiation. Diseases associated with tyrosine kinase activity include proliferation of tumour cells, pathological neovascularisation that promotes the growth of solid tumours, ocular neovascularisation (diabetic retinopathy, age-induced macular degeneration and the like) and inflammation (psoriasis, rheumatoid arthritis and the like).

The compounds of the formula I can be administered to patients for the treatment of cancer, in particular fast-growing tumours.

The invention thus relates to the use of compounds of the formula I according to Claim 1, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.

Preference is given here to Met kinase.

Preference is given to the use of compounds of the formula I according to Claim 1, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,

for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of tyrosine kinases by the compounds according to Claim 1.

Particular preference is given to the use for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of Met kinase by the compounds according to Claim 1.

Especial preference is given to the use for the treatment of a disease where the disease is a solid tumour.

The solid tumour is preferably selected from the group of tumours of the lung, of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach and/or of the larynx.

The solid tumour is furthermore preferably selected from the group lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.

Preference is furthermore given to the use for the treatment of a tumour of the blood and immune system, preferably for the treatment of a tumour selected from the group of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

The disclosed compounds of the formula I according to Claim 1 can be administered in combination with other known therapeutic agents, including anticancer agents. As used here, the term "anticancer agent" relates to any agent which is administered to a patient with cancer for the purposes of treating the cancer.

The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:

(i) antiproliferative/antineoplastic/DNA-damaging agents and combinations thereof, as used in medical oncology, such as alkylating agents (for example cisplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chloroambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines, such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines, such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids, such as vincristine, vinblastine, vindesine and vinorelbine, and taxoids, such as

taxol and taxotere) ; topoisomerase inhibitors (for example epipodophyllotoxins, such as etoposide and teniposide, amsacrine, topotecan, irinotecan and camptothecin) and cell-differentiating agents (for example all-trans-retinoic acid, 13-cis-retinoic acid and fenretinide);

(ii) cytostatic agents, such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor downregulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progesterones (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase, such as finasteride;

(iii) agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors, such as marimastat, and inhibitors of urokinase plasminogen activator receptor function);

(iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM] and the anti-erbB1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors, such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;

(v) antiangiogenic agents, such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [AvastinTM], compounds such as those disclosed in published international patent applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other

mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin);

(vi) vessel-damaging agents, such as combretastatin A4 and compounds disclosed in international patent applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;

(vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-Ras antisense;

(viii) gene therapy approaches, including, for example, approaches for replacement of aberrant genes, such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches, such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme, and approaches for increasing patient tolerance to chemotherapy or radiotherapy, such as multi-drug resistance gene therapy; and

(ix) immunotherapy approaches, including, for example, ex-vivo and in-vivo approaches for increasing the immunogenicity of patient tumour cells, such as transfection with cytokines, such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches for decreasing T-cell anergy, approaches using transfected immune cells, such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines, and approaches using anti-idiotypic antibodies.

The medicaments from Table 1 below are preferably, but not exclusively, combined with the compounds of the formula I according to Claim 1.

Alkylating agents	Cyclophosphamide Busulfan Ifosfamide Melphalan Hexamethylmelamine Thiotepa Chloroambucil Dacarbazine Carmustine	Lomustine Procarbazine Altretamine Estramustine phosphate Mechloroethamine Streptozocin Temozolomide Semustine
-------------------	---	---

Platinum agents	Cisplatin Oxaliplatin Spiroplatin Carboxyphthalatoplatinum Tetraplatin Ormiplatin Iproplatin	Carboplatin ZD-0473 (AnorMED) Lobaplatin (Aetema) Satraplatin (Johnson Matthey) BBR-3464 (Hoffmann-La Roche) SM-11355 (Sumitomo) AP-5280 (Access)
Antimetabolites	Azacytidine Gemcitabine Capecitabine 5-Fluorouracil Floxuridine 2-Chlorodesoxyadenosine 6-Mercaptopurine 6-Thioguanine Cytarabine 2-Fluorodesoxycytidine Methotrexate Idatrexate	Tomudex Trimetrexate Deoxycoformycin Fludarabine Pentostatin Raltitrexed Hydroxyurea Decitabine (SuperGen) Clofarabine (Bioenvision) Irofulven (MGI Pharma) DMDC (Hoffmann-La Roche) Ethinylcytidine (Taiho)
Topoisomerase inhibitors	Amsacrine Epirubicin Etoposide Teniposide or mitoxantrone Irinotecan (CPT-11) 7-Ethyl-10-hydroxycamptothecin Topotecan Dexrazoxanet (TopoTarget) Pixantrone (Novuspharma) Rebeccamycin analogue (Exelixis) BBR-3576 (Novuspharma)	Rubitecan (SuperGen) Exatecan mesylate (Daiichi) Quinamed (ChemGenex) Gimatecan (Sigma- Tau) Diflomotecan (Beaufour-Ipsen) TAS-103 (Taiho) Elsamitrucin (Spectrum) J-107088 (Merck & Co) BNP-1350 (BioNumerik) CKD-602 (Chong Kun Dang) KW-2170 (Kyowa Hakko)
Antitumour antibiotics	Dactinomycin (Actinomycin D) Doxorubicin (Adriamycin) Deoxyrubicin Valrubicin Daunorubicin (Daunomycin) Epirubicin Therarubicin Idarubicin Rubidazon Plicamycin Porfiromycin Cyanomorpholinodoxorubicin Mitoxantron (Novantron)	Amonafide Azonafide Anthrapyrazole Oxantrazole Losoantrone Bleomycin sulfate (Blenoxan) Bleomycinic acid Bleomycin A Bleomycin B Mitomycin C MEN-10755 (Menarini) GPX-100 (Gem Pharmaceutica)

Antimitotic agents	Paclitaxel Docetaxel Colchicine Vinblastine Vincristine Vinorelbine Vindesine Dolastatin 10 (NCI) Rhizoxin (Fujisawa) Mivobulin (Warner-Lambert) Cemadotin (BASF) RPR 109881A (Aventis) TXD 258 (Aventis) Epothilone B (Novartis) T 900607 (Tularik) T 138067 (Tularik) Cryptophycin 52 (Eli Lilly) Vinflunine (Fabre) Auristatin PE (Teikoku Hormor BMS 247550 (BMS) BMS 184476 (BMS) BMS 188797 (BMS) Taxoprexin (Protarga)	SB 408075 (GlaxoSmithKline) E7010 (Abbott) PG-TXL (Cell Therapeutics) IDN 5109 (Bayer) A 105972 (Abbott) A 204197 (Abbott) LU 223651 (BASF) D 24851 (ASTA Medica) ER-86526 (Eisai) Combretastatin A4 (BMS) Isohomohalichondrin-B (PharmaMar) ZD 6126 (AstraZeneca) PEG-Paclitaxel (Enzon) AZ10992 (Asahi) IDN-5109 (Indena) AVLB (Prescient NeuroPharma) Azaepothilon B (BMS) BNP- 7787 (BioNumerik) CA-4-prodrug (OXIGENE) Dolastatin-10 (NrH) CA-4 (OXIGENE)
Aromatase inhibitors	Aminoglutethimide Letrozole Anastrozole Formestran	Exemestan Atamestan (BioMedicines) YM-511 (Yamanouchi)
Thymidylate synthase inhibitors	Pemetrexed (Eli Lilly) ZD-9331 (BTG)	Nolatrexed (Eximias) CoFactor™ (BioKeys)
DNA antagonists	Trabectedin (PharmaMar) Glufosfamide (Baxter International) Albumin + 32P (Isotope Solutions) Thymectacin (NewBiotics) Edotreotid (Novartis)	Mafosfamide (Baxter International) Apaziquone (Spectrum Pharmaceuticals) O6-benzylguanine (Paligent)
Farnesyl transferase inhibitors	Arglabin (NuOncology Labs) lonafarnib (Schering-Plough) BAY-43-9006 (Bayer)	Tipifarnib (Johnson & Johnson) Perillyl alcohol (DOR BioPharm)
Pump inhibitors	CBT-1 (CBA Pharma) Tariquidar (Xenova) MS-209 (Schering AG)	Zosuquidar trihydrochloride (Eli Lilly) Biricodar dicitrate (Vertex)

Histone acetyl transferase inhibitors	Tacedinaline (Pfizer) SAHA (Aton Pharma) MS-275 (Schering AG)	Pivaloyloxymethyl butyrate (Titan) Depsipeptide (Fujisawa)
Metalloproteinase inhibitors Ribonucleoside reductase inhibitors	Neovastat (Aeterna Laboratori) Marimastat (British Biotech) Gallium maltolate (Titan) Triapin (Vion)	CMT -3 (CollaGenex) BMS-275291 (Celltech) Tezacitabine (Aventis) Didox (Molecules for Health)
TNF-alpha agonists / antagonists	Virulizin (Lorus Therapeutics) CDC-394 (Celgene)	Revimid (Celgene)
Endothelin-A receptor antagonists	Atrasentan (Abbot) ZD-4054 (AstraZeneca)	YM-598 (Yamanouchi)
Retinoic acid receptor agonists	Fenretinide (Johnson & Johnson) LGD-1550 (ligand)	Alitretinoin (Ligand)
Immunomodulators	Interferon Oncophage (Antigenics) GMK (Progenics) Adenocarcinoma vaccine (Biomira) CTP-37 (AVI BioPharma) JRX-2 (Immuno-Rx) PEP-005 (Peplin Biotech) Synchrovax vaccines (CTL Immuno) Melanoma vaccine (CTL Immuno) p21-RAS vaccine (GemVax)	Dexosome therapy (Anosys) Pentrix (Australian Cancer Technology) JSF-154 (Tragen) Cancer vaccine (Intercell) Norelin (Biostar) BLP-25 (Biomira) MGV (Progenics) I3-Alethin (Dovetail) CLL-Thera (Vasogen)
Hormonal and antihormonal agents	Oestrogens Conjugated oestrogens Ethinylloestradiol Chlorotrianisene Idenestrol Hydroxyprogesterone caproate Medroxyprogesterone Testosterone Testosterone propionate Fluoxymesterone Methyltestosterone Diethylstilbestrol Megestrol Tamoxifen Toremofin Dexamethasone	Prednisone Methylprednisolone Prednisolone Aminoglutethimide Leuprolide Goserelin Leuporelin Bicalutamide Flutamide Octreotide Nilutamide Mitotan P-04 (Novogen) 2-Methoxyoestradiol (EntreMed) Arzoxifen (Eli Lilly)

Photodynamic agents	Talaporfin (Light Sciences) Theralux (Theratechnologies) Motexafin-Gadolinium (Pharmacyclics)	Pd-Bacteriopheophorbid (Yeda) Lutetium-Texaphyrin (Pharmacyclics) Hypericin
Tyrosine kinase inhibitors	Imatinib (Novartis) Leflunomide (Sugen/Pharmacia) ZD1839 (AstraZeneca) Erlotinib (Oncogene Science) Canertinib (Pfizer) Squalamine (Genaera) SU5416 (Pharmacia) SU6668 (Pharmacia) ZD4190 (AstraZeneca) ZD6474 (AstraZeneca) Vatalanib (Novartis) PKI166 (Novartis) GW2016 (GlaxoSmithKline) EKB-509 (Wyeth) EKB-569 (Wyeth)	Kahalide F (PharmaMar) CEP- 701 (Cephalon) CEP-751 (Cephalon) MLN518 (Millenium) PKC412 (Novartis) Phenoxodiol O Trastuzumab (Genentech) C225 (ImClone) rhu-Mab (Genentech) MDX-H210 (Medarex) 2C4 (Genentech) MDX-447 (Medarex) ABX-EGF (Abgenix) IMC-1C11 (ImClone)
Various agents	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo) Tocladesine (cyclic AMP agonist, Ribapharm) Alvocidib (CDK inhibitor, Aventis) CV-247 (COX-2 inhibitor, Ivy Medical) P54 (COX-2 inhibitor, Phytopharm) CapCell™ (CYP450 stimulant, Bavarian Nordic) GCS-100 (gal3 antagonist, GlycoGenesys) G17DT immunogen (gastrin inhibitor, Apton) Efaproxiral (oxygenator, Allos Therapeutics) PI-88 (heparanase inhibitor, Progen) Tesmififen (histamine antagonist, YM BioSciences) Histamine (histamine H2 receptor agonist, Maxim) Tiazofurin (IMPDH inhibitor, Ribapharm) Cilengitide (integrin antagonist, Merck KGaA) SR-31747 (IL-1 antagonist, Sanofi-Synthelabo)	BCX-1777 (PNP inhibitor, BioCryst) Ranpirinase (ribonuclease stimulant, Alfacell) Galarubicin (RNA synthesis inhibitor, Dong-A) Tirapazamine (reducing agent, SRI International) N-Acetylcysteine (reducing agent, Zambon) R-Flurbiprofen (NF-kappaB inhibitor, Encore) 3CPA (NF-kappaB inhibitor, Active Biotech) Seocalcitol (vitamin D receptor agonist, Leo) 131-I-TM-601 (DNA antagonist, TransMolecular) Eflornithin (ODC inhibitor, ILEX Oncology) Minodronic acid (osteoclast inhibitor, Yamanouchi) Indisulam (p53 stimulant, Eisai) Aplidin (PPT inhibitor, PharmaMar) Rituximab (CD20 antibody, Genentech)

CCI-779 (mTOR kinase inhibitor, Wyeth)	Gemtuzumab (CD33 antibody, Wyeth Ayerst)
Exisulind (PDE-V inhibitor, Cel Pathways)	PG2 (haematopoiesis promoter, Pharmagenesis)
CP-461 (PDE-V inhibitor, Cell Pathways)	Immunol™ (triclosan mouthwash, Endo)
AG-2037 (GART inhibitor, Pfizer)	Triacetylyridine (uridine product, Wellstat)
WX-UK1 (plasminogen activator inhibitor, Willex)	SN-4071 (sarcoma agent, Signature BioScience)
PBI-1402 (PMN stimulant, ProMetic LifeSciences)	TransMID-107™ (immunotoxin, KS Biomedix)
Bortezomib (proteasome inhibitor, Millennium)	PCK-3145 (apoptosis promoter, Procyon)
SRL-172 (T-cell stimulant, SR Pharma)	Doranidazole (apoptosis promoter, Pola)
TLK-286 (glutathione-S transferase inhibitor, Telik)	CHS-828 (cytotoxic agent, Lederle)
PT-100 (growth factor agonist, Point Therapeutics)	Trans-retinoic acid (differentiator, NIH)
Midostaurin (PKC inhibitor, Novartis)	MX6 (apoptosis promoter, MAXIA)
Bryostatatin-1 (PKC stimulant, GPC Biotech)	Apomine (apoptosis promoter, ILEX Oncology)
CDA-II (apoptosis promoter, Everlife)	Urocidin (apoptosis promoter, Bioniche)
SDX-101 (apoptosis promoter, Salmedix)	Ro-31-7453 (apoptosis promoter, La Roche)
Ceflatonin (apoptosis promoter, ChemGenex)	Brostallicin (apoptosis promoter, Pharmacia)

A combined treatment of this type can be achieved with the aid of simultaneous, consecutive or separate dispensing of the individual components of the treatment. Combination products of this type employ the compounds according to the invention.

ASSAYS

The compounds of the formula I described in the examples were tested by the assays described below and were found to have kinase inhibitory activity. Other assays are known from the literature and could readily be performed by the person skilled in the art (see, for example, Dhanabal et al., *Cancer Res.* 59:189-197; Xin et al., *J. Biol. Chem.* 274:9116-9121; Sheu et al., *Anticancer Res.*

18:4435-4441; Ausprunk et al., *Dev. Biol.* 38:237-248; Gimbrone et al., *J. Natl. Cancer Inst.* 52:413-427; Nicosia et al., *In Vitro* 18:538- 549).

Measurement of Met kinase activity

According to the manufacturer's data (Met, active, upstate, catalogue No. 14-526), Met kinase is expressed for the purposes of protein production in insect cells (Sf21; *S. frugiperda*) and subsequent affinity-chromatographic purification as "N-terminal 6His-tagged" recombinant human protein in a baculovirus expression vector.

The kinase activity can be measured using various available measurement systems. In the scintillation proximity method (Sorg et al., *J. of Biomolecular Screening*, 2002, 7, 11-19), the flashplate method or the filter binding test, the radioactive phosphorylation of a protein or peptide as substrate is measured using radioactively labelled ATP (^{32}P -ATP, ^{33}P -ATP). In the case of the presence of an inhibitory compound, a reduced radioactive signal, or none at all, can be detected. Furthermore, homogeneous time-resolved fluorescence resonance energy transfer (HTR-FRET) and fluorescence polarisation (FP) technologies can be used as assay methods (Sills et al., *J. of Biomolecular Screening*, 2002, 191-214).

Other non-radioactive ELISA assay methods use specific phospho-antibodies (phospho-ABs). The phospho-antibody only binds the phosphorylated substrate. This binding can be detected by chemiluminescence using a second peroxidase-conjugated antibody (Ross et al., 2002, *Biochem. J.*).

Flashplate method (Met kinase)

The test plates used are 96-well Flashplate^R microtitre plates from Perkin Elmer (Cat. No. SMP200). The components of the kinase reaction described below are pipetted into the assay plate.

The Met kinase and the substrate poly Ala-Glu-Lys-Tyr, (pAGLT, 6:2:5:1), are incubated for 3 hrs at room temperature with radioactively labelled ^{33}P -ATP in the presence and absence of test substances in a total volume of 100 μl . The reaction is terminated using 150 μl of a 60 mM EDTA solution. After incubation for a further 30 min at room temperature, the supernatants are filtered off with suction, and the

wells are washed three times with 200 µl of 0.9% NaCl solution each time. The measurement of the bound radioactivity is carried out by means of a scintillation measuring instrument (Topcount NXT, Perkin-Elmer).

The full value used is the inhibitor-free kinase reaction. This should be approximately in the range 6000-9000 cpm. The pharmacological zero value used is staurosporin in a final concentration of 0.1 mM. The inhibitory values (IC₅₀) are determined using the RS1_MTS program.

Kinase reaction conditions per well:

30 µl of assay buffer

10 µl of substance to be tested in assay buffer with 10% of DMSO

10 µl of ATP (final concentration 1 µM cold, 0.35 µCi of ³³P-ATP)

50 µl of Met kinase/substrate mixture in assay buffer;

(10 µg of enzyme/well, 50 ng of pAGLT/well)

Solutions used:

- Assay buffer:

50 mM HEPES

3 mM magnesium chloride

3 µM sodium orthovanadate

3 mM manganese(II) chloride

1 mM dithiothreitol (DTT)

pH = 7.5 (to be set using sodium hydroxide)

- Stop solution:

60 mM Titriplex III (EDTA)

- ³³P-ATP: Perkin-Elmer;

- Met kinase: Upstate, Cat. No. 14-526, Stock 1 µg/10 µl; spec. activity 954 U/mg;

- Poly-Ala-Glu-Lys-Tyr, 6 : 2 : 5 : 1 : Sigma Cat. No. P1152

In-vivo tests (Fig. 1/1)

Experimental procedure: Female Balb/C mice (breeder: Charles River Wiga) were 5 weeks old on arrival. They were acclimatised to our keeping conditions for 7 days. Each mouse was subsequently injected subcutaneously in the pelvic area

with 4 million TPR-Met/NIH3T3 cells in 100 µl of PBS (without Ca⁺⁺ and Mg⁺⁺). After 5 days, the animals were randomised into 3 groups, so that each group of 9 mice had an average tumour volume of 110 µl (range: 55 – 165). 100 µl of vehicle (0.25% methylcellulose/ 100 mM acetate buffer, pH 5.5) were administered daily to the control group, and 200 mg/kg of "A56" or "A91" dissolved in the vehicle (volume likewise 100 µl/animal) were administered daily to the treatment groups, in each case by gastric tube. After 9 days, the controls had an average volume of 1530 µl and the experiment was terminated.

Measurement of the tumour volume: The length (L) and breadth (B) were measured using a Vernier calliper, and the tumour volume was calculated from the formula $L \times B \times B/2$.

Keeping conditions: 4 or 5 animals per cage, feeding with commercial mouse food (Sniff).

The compounds "A18" and "A22" have a significant antitumoural action.

Above and below, all temperatures are indicated in °C. In the following examples, "conventional work-up" means: water is added if necessary, the pH is adjusted, if necessary, to values between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the residue is purified by chromatography on silica gel and/or by crystallisation. R_f values on silica gel; eluent: ethyl acetate/methanol 9:1.

Mass spectrometry (MS): EI (electron impact ionisation) M⁺

FAB (fast atom bombardment) (M+H)⁺

ESI (electrospray ionisation) (M+H)⁺

APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry) (M+H)⁺.

Mass spectrometry (MS): EI (electron impact ionisation) M⁺

FAB (fast atom bombardment) (M+H)⁺

ESI (electrospray ionisation) (M+H)⁺

APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry) (M+H)⁺.

M.p. = melting point

HPLC methods:

HPLC/MS analyses

are carried out in a 3 μ Silica-Rod column with a 210 second gradient from 20 to 100% water/acetonitrile/0.01% of trifluoroacetic acid, at a flow rate of 2.2 ml/min, and detection at 220 nm.

HPLC analyses (Method A)

Column: Chromolith RP18e 100*3 mm

Flow rate: 2 ml/min

Solvent A: H₂O + 0.1% of trifluoroacetic acid

Solvent B: acetonitrile + 0.1% of trifluoroacetic acid

Gradient 5 min

0-4 min: 99:1 -> 1:99

4-5 min: 1:99 – 1:99

HPLC analyses (Method B)

Column: Chromolith RP18e 100*3 mm

Flow rate: 2 ml/min

99:01 - 0:100 water + 0.1% (vol.) of TFA : acetonitrile + 0.1% (vol.) of TFA

0.0 to 0.2 min: 99:01

0.2 to 3.8 min: 99:01--> 0:100

3.8 to 4.2 min: 0:100

Wavelength: 220nm

HPLC analysis (Method C)

Column: Chromolith RP18e 100*3 mm

Flow rate: 2 ml/min

99:01 - 0:100 water + 0.01% (vol.) of formic acid : acetonitrile + 0.01% (vol.) of formic acid

0.0 to 0.2 min: 99:01

0.2 to 3.8 min: 99:01--> 0:100

3.8 to 4.2 min: 0:100

Wavelength: 220nm

HPLC analysis (Method D)

Column: Chromolith RP18e 100*3 mm

Flow rate: 2 ml/min

99:01 - 0:100 water + 0.05% (vol.) of formic acid : acetonitrile + 0.05% (vol.) of formic acid

0.0 to 0.2 min: 99:01

0.2 to 3.8 min: 99:01 → 0:100

3.8 to 4.2 min: 0:100


Wavelength: 220nm

Retention time Rt in minutes [min].

Examples of the preparation of the pyridazinone starting compounds

The pyridazinones are generally prepared by processes from W. H. Coates, A. McKillop, *Synthesis* 1993, p. 334.


An example thereof is the synthesis of 3-(6-oxo-1,6-dihydropyridazin-3-yl)-benzonitrile:



927 g (10.6 mol) of glyoxylic acid monohydrate are introduced in portions into a solution of 1278 g (8.80 mol) of 3-acetylbenzonitrile in 1.5 l of acetic acid. The resultant solution is heated at 95°C for 18 hours. The mixture is allowed to cool to 30°C, and 7 l of water and 899 ml (18.5 mol) of hydrazinium hydroxide are added successively. The reaction mixture is stirred at 95°C for 4 hours. The mixture is allowed to cool to 60°C, and the resultant precipitate is filtered off with suction and washed with 5 l of water and 2 l of acetone. The residue is heated to the boil in 5 l of acetone and filtered off with suction while hot. 5 l of acetic acid are added to the residue, and the mixture is heated at 90°C for 2 hours with stirring. The mixture is allowed to cool to room temperature, and the residue is filtered off with suction and washed with acetone. The residue is again heated to 90°C with 5 l of acetic acid, cooled to room temperature, filtered off with suction and washed with acetone. The residue is dried in

vacuo: 3-(6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile as beige crystals; ESI 198.

Some pyridazinones can be prepared in accordance with A. J. Goodman et al., *Tetrahedron* 55 (1999), 15067-15070. An example thereof is the alternative synthesis of 3-(6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile:




2.70 kg (18.0 mol) of sodium iodide are added in portions at room temperature to a mixture of 5.0 l of water and 11.3 l of 57% aqueous hydroiodic acid (75.2 mol). 2.00 kg (13.4 mol) of 3,6-dichloropyridazine are subsequently added in portions to the solution held at 20°C. The reaction mixture is stirred at 20°C for 18 hours. 10 l of tert-butyl methyl ether and 4 l of water are added to the reaction mixture. The organic phase is separated off and washed with water and aqueous sodium sulfite solution. The organic phase is concentrated, heptane is added, and the resultant solid is filtered off with suction and washed with heptane. The residue is dried in vacuo: 3-chloro-6-iodopyridazine as colourless leaf-shaped crystals; ESI 241.

A solution of 212 mg (2.0 mmol) of sodium carbonate in 1 ml of water is added to a solution, kept under nitrogen, of 240 mg (1.00 mmol) of 3-chloro-6-iodopyridazine in 1 ml of toluene, and the mixture is heated to 80°C. 7.0 mg (0.010 mmol) of bis(triphenylphosphine)palladium(II) chloride are added, and a solution of 147 mg (1.00 mmol) of 3-cyanobenzeneboronic acid is subsequently added dropwise. The reaction mixture is stirred at 80°C for 18 hours. The reaction mixture is cooled to room temperature, water is added, and the solid is filtered off with suction and washed with water. The residue is dried in vacuo: 3-(6-chloropyridazin-3-yl)benzonitrile as colourless crystals; ESI 216.

A suspension of 85 mg (0.396 mol) of 3-(6-chloropyridazin-3-yl)benzonitrile in 0.5 ml of acetic acid is heated to 80°C and stirred at this temperature for 24 hours. The reaction mixture is cooled to room temperature, water is added, and the solid is filtered off with suction. The residue is washed with water and dried in vacuo: 3-(6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile as colourless crystals.

Some pyridazinones are prepared by the following process. An example thereof is the synthesis of 6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one:




705 g (3.39 mol) of 1-methyl-1H-pyrazole-4-boronic acid pinacol ester and 1.44 kg of tripotassium phosphate trihydrate are added to a solution of 815 g (3.39 mol) of 3-chloro-6-iodopyridazine in 3.8 l of 1,2-dimethoxyethane. The resultant suspension is heated to 80°C under nitrogen and with stirring, and 59.5 g (85 mmol) of bis(triphenylphosphine)palladium(II) chloride are added. The reaction mixture is stirred at 80°C for 3 hours. The mixture is allowed to cool to room temperature, and 9 l of water are added. The resultant precipitate is filtered off with suction, washed with water and dried in vacuo: 3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine as brown crystals; ESI 195.

A suspension of 615 g (2.90 mol) of 3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine in a mixture of 1.86 l of formic acid and 2.61 l of water is heated to 80°C with stirring and stirred at this temperature for 28 hours. The reaction mixture is cooled to room temperature, a little activated carbon is added, and the solid is filtered off with suction. The filtrate is adjusted to a pH of 7 using 40% aqueous sodium hydroxide solution with ice cooling and left at 6°C for 16 h. The resultant precipitate is filtered off with suction, washed with water and dried in

vacuo: 6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one as colourless crystals; ESI 177.

Preparation of 5-bromo-2-(3-chloromethylphenyl)pyrimidine:



Step a:

750 mg (0.65 mmol) of tetrakis(triphenylphosphine)palladium are added to a solution, kept under nitrogen, of 6.11 g (21.5 mmol) of 5-bromo-2-iodopyrimidine, 3.91 g (25.7 mmol) of 3-(hydroxymethyl)benzeneboronic acid and 9.11 g (42.9 mmol) of tripotassium phosphate trihydrate in 120 ml of dioxane and 14 ml of water, and the mixture is stirred at 90°C for 18 hours. The reaction mixture is cooled to room temperature, *tert*-butyl methyl ether and water are added, and the mixture is filtered through kieselguhr. The organic phase of the filtrate is separated off, dried over sodium sulfate and evaporated. The residue is chromatographed on a silica-gel column with dichloromethane/methanol as eluent:


product: 2.49 g; m.p. 114-117°, ESI: 265, 267 (M+H), HPLC: Rt. = 2.51 min (method B).

Step b:

80 g (302 mmol) of [3-(5-bromopyrimidin-2-yl)phenyl]methanol are suspended in 300 ml of dichloromethane, and 33 ml (453 mmol) of thionyl chloride are slowly added with cooling. The reaction mixture is stirred at room temperature for 3 h. The solvent was distilled off, co-evaporated 3 times with toluene and stirred with diethyl ether:

pale-yellow crystals, m.p. 146-148°, HPLC: Rt. = 3.15 min (method B).

Preparation of 2-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one:



12.4 g (43.6 mmol) of 5-bromo-2-(3-chloromethylphenyl)pyrimidine and 14.2 g (43.6 mmol) of caesium carbonate are added to a suspension of 7.68 g (43.6 mmol) of 6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one in 90 ml of DMF, and the mixture is stirred at room temperature for 24 hours. The reaction mixture is added to 400 ml of water. The precipitate formed is filtered off with suction, washed with water and dried in vacuo; 2-[3-(5-bromopyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one as yellow-brown crystals; m.p. 184°C; ESI 423, 425.


10.9 g (42.9 mmol) of bis(pinacolato)diboron and 9.72 g (99.0 mmol) of potassium acetate are added to a suspension of 14.0 g (33.0 mmol) of 2-[3-(5-bromopyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one in 65 ml of DMF, and the mixture is heated to 70°C under nitrogen. After the mixture has been stirred at this temperature for 15 minutes, 695 mg (0.99 mmol) of bis(triphenylphosphine)-palladium(II) chloride are added, and the reaction mixture is stirred at 70°C under nitrogen for 18 hours. The reaction mixture is allowed to cool to room temperature, water and dichloromethane are added, the mixture is filtered through kieselguhr, and the organic phase is separated off. The organic phase is dried over sodium sulfate, evaporated, and the residue is recrystallised from 2-propanol: 6-(1-methyl-1H-

pyrazol-4-yl)-2-{3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]benzyl}-2H-pyridazin-3-one as grey crystals; m.p. 204°C;

¹H-NMR (d₆-DMSO): δ [ppm] = 1.34 (s, 12H), 3.87 (s, 3H), 5.35 (s, 2H), 7.05 (d, J = 9.6 Hz, 1H), 7.52 (m, 2H), 7.80 (d, J = 9.6 Hz, 1H), 7.89 (s, 1H), 8.21 (s, 1H), 8.35 (m, 1H), 8.45 (bs, 1H), 9.01 (s, 2H).

8.50 g (85.1 mmol) of sodium perborate are added in portions with ice-cooling to a suspension of 13.4 g (28.4 mmol) of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]benzyl}-2H-pyridazin-3-one in 55 ml of THF and 55 ml of water, and the mixture is stirred at room temperature for 2 hours. The reaction mixture is filtered off through kieselguhr with suction. The filtrate is evaporated to about half of the original volume in vacuo and adjusted to a pH of 1 using 2 N hydrochloric acid. The precipitate formed is filtered off with suction, washed with water and dried in vacuo: 2-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one as pale-beige crystals; m.p. 239°C; ESI 361.

Preparation of 3-{1-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydropyridazin-3-yl}benzonitrile:



Step 1:

61.13 g of 3-cyanophenylpyridazinone (0.31 mol) and 87.9 g of 5-bromo-2-(3-chloromethylphenyl)pyrimidine (0.31 mol) are dissolved in 610 ml of DMF in a 1000 ml one-necked flask under an inert-gas atmosphere, and 111.11 g of caesium

carbonate (0.34 mol) are subsequently added. The reaction mixture is stirred at 40°C for 72 h. For work-up, the mixture is diluted with 600 ml of water with stirring, the precipitate formed is washed with copious water and a little methanol and chromatographed on 1 kg of silica gel. The product fractions are combined, evaporated to dryness in a rotary evaporator, and the product is slurried with a little methanol, filtered off with suction and dried at 70°C in vacuo; m.p. 178-9°C.

Step 2:


35.57 g of 3-[1-[3-(5-bromopyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile (0.08 mol), 26.43 g of bis(pinacolato)diborate (0.104 mol) and 23.75 g of potassium acetate (0.240 mol) are suspended in 165 ml of abs. DMF in a 500 ml three-necked flask under an N₂ atmosphere, heated to 70°C with stirring, 1.686 g of (PPh₃)₂PdCl₂ (2.4 mmol) are subsequently added, and the reaction batch is stirred at 70°C for 6h during which a dark-brown solution forms. For work-up, the reaction mixture is diluted with 600 ml of water at RT with stirring, and the precipitate formed is filtered off with suction. The precipitate formed is taken up in 500 ml of dichloromethane, shaken 2x with 200 ml of water, dried over sodium sulfate and evaporated to dryness. The residue is slurried in 200 ml of acetone, filtered off with suction and washed with a little acetone, m.p. 203-5°C.

Step 3:

50.46 g of 3-(6-oxo-1-[3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]benzyl]-1,6-dihydropyridazin-3-yl)benzonitrile (102.7 mmol) and 33.81 g of sodium perborate tetrahydrate (339 mmol) in a mixture of 220 ml of THF and 220 ml of water are mixed in a 1000 ml one-necked flask and stirred at room temperature for 2 h, during which a pale precipitate deposits. The reaction mixture is diluted with 800 ml of dichloromethane, shaken with 500 ml of saturated aqueous ammonium chloride solution, dried over sodium sulfate and evaporated to dryness in a rotary evaporator. The residue is slurried in methanol, filtered off with suction and washed with diethyl ether, m.p. 245-8°C.

Examples

Preparation of (2S,3S)-2-amino-3-methoxy-N-[2-(2-[3-(3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl)pyrimidin-5-yloxy)ethyl]butyramide ("A1")



Step a:

721 mg (2 mmol) of 2-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one are dissolved in 10 ml of DMF, and 1g (3 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 347 μ l (2.2 mmol) of *tert*-butyl *N*-(2-hydroxyethyl)carbamate are added. The reaction mixture is shaken at room temperature for 15 min, and 705 mg (3 mmol) of di-*tert*-butyl azodicarboxylate are subsequently added. The reaction mixture is shaken at room temperature for 3 h, a further 500 mg (1.5 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 352 mg (1.5 mmol) of di-*tert*-butyl azodicarboxylate are added, and the mixture is shaken at room temperature for 18 h. The reaction mixture is filtered off through kieselguhr with suction and washed with a little methanol. The filtrate is evaporated to dryness and chromatographed by means of column chromatography on silica gel;

HPLC: Rt. = 2.83 min (method C), ESI: 504 (M+H).

Step b:

977 mg (1.94 mmol) of *tert*-butyl [2-(2-{3-[3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)ethyl]carbamate ("B1") are dissolved in 10 ml of dioxane, and 9.7 ml of 4N HCl in dioxane are added. The mixture is stirred at room temperature for 8 h, the precipitate formed is filtered off with suction, rinsed with dioxane and dried in vacuo; HPLC: Rt. = 2.89 min (method C), ESI: 404 (M+H).


Step c:

100 mg (0.23 mmol) of 2-{3-[5-(2-aminoethoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one hydrochloride, 58 mg (0.25 mmol) of (2S,3S)-2-*tert*-butoxycarbonylamino-3-methoxybutyric acid, 66 mg (0.34 mmol) of EDCI, 41 mg (0.30 mmol) of HOBT are dissolved in 2 ml of DMF, and 76 μ l (0.68 mmol) of 4-methylmorpholine are added. The reaction mixture is stirred at room temperature for 18 h, ethyl acetate is added, and the mixture is washed with water. The organic phase is dried and stripped off to dryness. The crude product is dissolved in 2 ml of dioxane, and 2 ml of 4N HCl in dioxane are added. The reaction mixture is stirred at room temperature for 12 h, evaporated and purified by means of preparative HPLC; HPLC: Rt. = 2.03 min (method C), ESI: 519 (M+H). The product "A1" is in the form of the trifluoroacetate;

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.63 (s, 2H), 8.28 (s, 1H), 8.24 – 8.15 (m, 3H), 7.88 (s, 1H), 7.80 (d, J = 9.6, 1H), 7.52 – 7.38 (m, 2H), 7.05 (d, J = 9.6, 1H), 5.33 (s, 2H), 4.23 (t, J = 5.6, 2H), 3.87 (s, 3H), 3.66 – 3.58 (m, 1H), 3.57 – 3.45 (m, 2H), 3.17 (s, 3H), 3.04 (d, J = 3.7, 1H), 1.06 (d, J = 6.3, 3H).

The following compounds are synthesised analogously to the preparation of "A1":


N-[2-(2-{3-[3-(1-Methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)ethyl]-(2S,4R)-4-hydroxypyrrolidine-2-carboxamide ("A2")



HPLC: Rt. = 1.94 min (method C), ESI: 517 (M+H); the product is in the form of the trifluoroacetate;

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.63 (s, 2H), 8.28 (s, 1H), 8.21 (m, 3H), 8.17 (s, 1H), 7.88 (s, 1H), 7.80 (d, $J = 9.6$, 1H), 7.45 (dt, $J = 7.6$, 15.0, 2H), 7.05 (d, $J = 9.6$, 1H), 5.33 (s, 2H), 4.80 – 4.45 (b, 1H), 4.22 (t, $J = 5.7$, 2H), 4.14 (s, 1H), 3.87 (s, 3H), 3.74 (t, $J = 8.2$, 1H), 3.49 (dd, $J = 5.7$, 11.5, 3H), 2.76 (dd, $J = 7.6$, 15.1, 2H), 1.99 – 1.88 (m, 1H), 1.72 – 1.58 (m, 1H).


N-2-(2-(3-(3-(1-Methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl)phenyl)pyrimidin-5-yloxy)ethyl)-(S)-pyrrolidine-2-carboxamide ("A3")



HPLC: Rt. = 2.00 min (method C), ESI: 501 (M+H); the product is in the form of the trifluoroacetate;

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.64 (s, 2H), 8.28 (s, 1H), 8.22 (m, 3H), 7.89 (s, 1H), 7.81 (d, $J = 9.6$, 1H), 7.53 – 7.40 (m, 2H), 7.06 (d, $J = 9.6$, 1H), 5.33 (s, 2H), 4.23 (t, $J = 5.6$, 2H), 3.87 (s, 3H), 3.57 (dd, $J = 5.5$, 8.8, 1H), 3.50 (d, $J = 5.9$, 2H), 2.81 (ddd, $J = 3.7$, 10.2, 16.6, 2H), 1.94 (s, 1H), 1.66 – 1.51 (m, 3H).


N-2-(2-(3-(3-(3-Cyanophenyl)-6-oxo-6H-pyridazin-1-ylmethyl)phenyl)pyrimidin-5-yloxy)ethyl)-(2S,4R)-4-hydroxypyrrolidine-2-carboxamide ("A4")



HPLC: Rt. = 2.41 min (method B), ESI: 538 (M+H); the product is in the form of the trifluoroacetate;

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 9.65 (s, 1H), 8.85 (t, 1H), 8.63-8.74 (m, 3H), 8.38 (d, J = 8.6, 2H), 8.25 (m, 2H), 8.17 (d, J = 9.8, 1H), 7.93 (d, J = 7.7, 1H), 7.72 (t, J = 7.9, 1H), 7.56 – 7.43 (m, 2H), 7.29 – 6.99 (m, 2H), 5.45 (s, 2H), 4.43 (s, 1H), 4.27 (m, 3H), 3.58 (m, 2H), 3.31 (m, 2H), 3.04 - 3.13 (m, 1H), 2.33 – 2.17 (m, 1H), 2.00 – 1.80 (m, 1H).


N-[2-(2-{3-[3-(3-Cyanophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)ethyl]-L-pyrrolidine-2-carboxamide ("A5")



HPLC: Rt. = 2.47 min (method B), ESI: 522 (M+H); the product is in the form of the trifluoroacetate;

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 9.28 (s, 1H), 8.79 (t, J = 5.5, 1H), 8.66 (s, 2H), 8.55 (b, 1H), 8.38 (d, J = 9.3, 2H), 8.28 – 8.21 (m, 2H), 8.17 (d, J = 9.8, 1H), 7.93 (d, J = 7.7, 1H), 7.72 (t, J = 7.9, 1H), 7.56 – 7.42 (m, 2H), 7.16 (d, J = 9.7, 1H), 5.45 (s, 2H), 4.33 – 4.24 (m, 2H), 4.16 (s, 2H), 3.65 – 3.51 (m, 2H), 3.32 – 3.11 (m, 1H), 2.26 (dt, J = 10.4, 22.4, 1H), 1.92 – 1.79 (m, 3H).


(2*S*,3*S*)-2-Amino-N-[2-(2-{3-[3-(3-cyanophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}pyrimidin-5-yloxy)ethyl]-3-methoxybutyramide ("A6")



HPLC: Rt. = 2.47 min (method B), ESI: 540 (M+H); the product is in the form of the trifluoroacetate;

¹H NMR (500 MHz, DMSO-*d*₆) δ [ppm] 8.81 (t, *J* = 5.5, 1H), 8.65 (s, 2H), 8.38 (d, *J* = 10.3, 2H), 8.28 – 8.22 (m, 2H), 8.12 – 8.22 (m, 4H), 7.92 (d, *J* = 7.8, 1H), 7.72 (t, *J* = 7.9, 1H), 7.56 – 7.42 (m, 2H), 7.15 (d, *J* = 9.8, 1H), 5.44 (s, 2H), 4.27 (m, 2H), 3.67 (m, 2H), 3.62 – 3.47 (m, 2H), 3.27 (s, 3H), 1.14 (d, *J* = 6.2, 3H).

Preparation of (*S*)-2-acetylamino-3-methyl-N-[2-(2-{3-[3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)ethyl]butyramide ("A7")



100 mg (0.23 mmol) of 2-(2-{3-[5-(2-aminoethoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one hydrochloride, 43 mg (0.25 mmol) of (*S*)-2-acetylamino-3-methylbutyric acid, 66 mg (0.34 mmol) of EDCI, 41 mg (0.30 mmol) of HOBt are dissolved in 2 ml of DMF, and 76 μ l (0.68 mmol) of 4-methylmorpholine


are added. The reaction mixture is stirred at room temperature for 18 h, water is added, and the precipitate is stirred with methanol and dichloromethane. The product is dried in vacuo.

HPLC: Rt. = 2.37 min (method B), ESI: 545 (M+H);

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.62 (s, 2H), 8.28 (s, 1H), 8.19 – 8.25 (m, 3H), 7.88 (s, 1H), 7.84 (d, J = 8.9, 1H), 7.80 (d, J = 9.6, 1H), 7.52 – 7.38 (m, 2H), 7.05 (d, J = 9.6, 1H), 5.33 (s, 2H), 4.21 (t, J = 5.5, 2H), 4.16 – 4.04 (m, 1H), 3.58 – 3.37 (m, 2H), 1.91 (dt, J = 6.6, 13.6, 1H), 1.85 (s, 3H), 0.82 (d, J = 6.8, 6H).

The following is obtained analogously:

(S)-2-acetylamino-N-[2-(2-{3-[3-(3-cyanophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl]pyrimidin-5-yloxy)ethyl]-3-methylbutyramide ("A8")




HPLC: Rt. = 2.76 min (method B), ESI: 566 (M+H);

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.65 (s, 2H), 8.43 (s, 1H), 8.38 (s, 1H), 8.26 (d, J = 7.2, 2H), 8.17 (d, J = 9.8, 1H), 7.91 (d, J = 7.6, 1H), 7.72 (t, J = 7.7, 1H), 7.45-7.55 (m, 2H), 7.16 (d, J = 9.7, 1H), 5.47 (s, 2H), 4.24 (m, 2H), 4.15 (d, J = 7.0, 1H), 3.43-3.61 (m, 2H), 1.95 (m, 1H), 1.89 (s, 3H), 0.85 (d, J = 6.6, 6H).

Reference example:

Preparation of methyl (2S,4S)-4-(2-{3-[3-(3-cyanophenyl)-6-oxo-6H-pyridazin-1-yl(methyl)phenyl]pyrimidin-5-yloxy}pyrrolidine-2-carboxylate ("A9")




191 mg (0.5 mmol) of 3-(1-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile are dissolved in 6 ml of DMF, and 250 mg (0.75 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 80 mg (0.55 mmol) of methyl (2S,4R)-4-hydroxypyrrolidine-2-carboxylate are added. The reaction mixture is shaken at room temperature for 15 min, and 176 mg (0.75 mmol) of di-*tert*-butyl azodicarboxylate are subsequently added. The reaction mixture is shaken at room temperature for 3 h, a further 250 mg (0.75 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 176 mg (0.75 mmol) of di-*tert*-butyl azodicarboxylate are added, and the mixture is shaken at room temperature for 18 h. The reaction mixture is filtered off through kieselguhr with suction and washed with a little acetonitrile. The filtrate is evaporated to dryness and purified by means of preparative HPLC.

HPLC: Rt. = 2.53 min (method B), ESI: 509 (M+H); the product is in the form of the trifluoroacetate.

Reference example:

Preparation of (2S,4S)-4-(2-{3-[3-(3-cyanophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}pyrimidin-5-yloxy)pyrrolidine-2-carboxylic acid ("A10")




200 mg (0.52 mmol) of 3-[1-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile are dissolved in 6 ml of DMF, and 262 mg (0.79 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 146 mg (0.58 mmol) of (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-*tert*-butyl ester are added. The reaction mixture is shaken at room temperature for 15 min, and 185 mg (0.79 mmol) of di-*tert*-butyl azodicarboxylate are subsequently added. The reaction mixture is shaken at room temperature for 3 h, a further 262 mg (0.79 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 185 mg (0.79 mmol) of di-*tert*-butyl azodicarboxylate are added, and the mixture is shaken at room temperature for 18 h. The reaction mixture is filtered off through kieselguhr with suction and washed with ethyl acetate. Ethyl acetate is added to the filtrate, which is then washed with 1N HCl and saturated sodium hydrogencarbonate solution and purified by means of preparative HPLC. 1 ml of 4N HCl in dioxane is added to the intermediate, the mixture is stirred at room temperature for 15 h, evaporated and purified by means of preparative HPLC.

HPLC: Rt. = 2.31 min (method D), ESI: 494 (M+H); the product is in the form of the trifluoroacetate.

The following are prepared analogously:


(S)-2-Amino-5-(2-{3-[3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}pyrimidin-5-yloxy)pentanoic acid ("A11")



HPLC: Rt. = 2.04 min (method D), ESI: 475 (M+H); the product is in the form of the trifluoroacetate;

¹H NMR (500 MHz, DMSO-d₆) δ [ppm] 8.62 (d, *J* = 3.0, 2H), 8.28 (s, 1H), 8.21 (s, 2H), 7.88 (s, 1H), 7.80 (d, *J* = 9.6, 1H), 7.45 (m, 2H), 7.05 (d, *J* = 9.6, 1H), 5.33 (s, 2H), 4.19 (t, *J* = 6.1, 2H), 3.87 (b, 3H), 3.17 (m, 2H), 1.87 (m, 3H), 1.78 – 1.67 (m, 1H).

Preparation of 2-{3-[5-(4-dimethylaminomethylcyclohexylmethoxy)pyrimidin-2-yl]-benzyl}-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one ("A13")



Step 1:

100 mg (0.28 mmol) of 2-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one are dissolved in 6 ml of DMF, and 277 mg (0.83 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 78 mg (0.32 mmol) of *tert*-butyl (4-hydroxymethylcyclohexylmethyl)carbamate (preparation analogous to WO2008/040934) are added. The reaction mixture is shaken at room temperature for 15 min, and 196 mg (0.83 mmol) of di-*tert*-butyl azodicarboxylate are subsequently added. The reaction mixture is shaken at room temperature for 3 h, a further 277 mg (0.83 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 196 mg (0.83 mmol) of di-*tert*-butyl azodicarboxylate are added, and the mixture is shaken at room temperature for 18 h. The reaction mixture is filtered off through kieselguhr with suction and washed with ethyl acetate. The filtrate is evaporated and purified by means of preparative HPLC. 1 ml of 4N HCl in dioxane is added to the intermediate, the mixture is stirred at room temperature for 15 h and evaporated.

HPLC: Rt. = 2.19 min (method C), ESI: 486 (M+H); the product is in the form of the hydrochloride.

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.64 (d, J = 9.9, 2H), 8.28 (s, 1H), 8.21 (m, 2H), 7.96 (b, 3H), 7.89 (s, 1H), 7.81 (d, J = 9.6, 1H), 7.45 (m, 2H), 7.05 (d, J = 9.6,

1H), 5.33 (s, 2H), 4.12 (d, $J = 7.0$, 1H), 4.02 (d, $J = 6.4$, 1H), 2.70 - 2.80 (m, 1H), 2.70 - 2.59 (m, 1H), 1.80-1.91 (m, 3H), 1.78 - 1.69 (m, 1H), 1.42 - 1.62 (m, 4H), 1.13 - 0.93 (m, 2H).

Step 2:


40 mg (0.077 mmol) of 2-[3-[5-(4-aminomethylcyclohexylmethoxy)pyrimidin-2-yl]benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one ("A13a") are dissolved in 2 ml of formic acid, and 24 μ l (0.31 mmol) of formaldehyde solution (35%) are added. The reaction mixture is stirred at 100°C for 48 h. The reaction mixture is evaporated and purified by means of preparative HPLC.

HPLC: Rt. = 2.25 min (method D), ESI: 514 (M+H);


^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.62 (d, $J = 5.8$, 2H), 8.28 (s, 1H), 8.21 (d, $J = 4.7$, 2H), 7.89 (s, 1H), 7.80 (d, $J = 9.7$, 1H), 7.52 - 7.37 (m, 2H), 7.05 (d, $J = 9.6$, 1H), 5.33 (s, 2H), 4.09 (d, $J = 7.0$, 1H), 4.00 (d, $J = 6.3$, 1H), 2.13 - 2.07 (m, 6H), 0.82 - 2.10 (m, 12H).

The following are prepared analogously:


3-(1-[3-[5-(4-Aminomethylcyclohexylmethoxy)pyrimidin-2-yl]benzyl]-6-oxo-1,6-dihydropyridazin-3-yl)benzotrile ("A13b")



3-(1-[3-[5-(2-Aminomethylcyclopropylmethoxy)pyrimidin-2-yl]benzyl]-6-oxo-1,6-dihydropyridazin-3-yl)benzotrile ("A13c")




2-{3-[5-(1-Aminomethylcyclopropylmethoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one ("A14")



HPLC: Rt. = 2.01 min (method D), ESI: 444 (M+H);

¹H NMR (500 MHz, DMSO-d₆) δ [ppm] 8.64 (s, 2H), 8.30 (s, 1H), 8.22 (d, *J* = 7.5, 2H), 8.05 (s, 3H), 7.89 (s, 1H), 7.82 (d, *J* = 9.6, 1H), 7.53 – 7.37 (m, 2H), 7.06 (d, *J* = 9.6, 1H), 5.33 (s, 2H), 4.15 (s, 2H), 2.94 (d, *J* = 5.6, 2H), 0.82 (d, *J* = 6.4, 2H), 0.72 (d, *J* = 5.2, 2H).


3-(1-{3-[5-(1-Aminomethylcyclopropylmethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile ("A15")



HPLC: Rt. = 2.29 min (method D), ESI: 465 (M+H);

¹H NMR (500 MHz, DMSO-d₆) δ [ppm] 8.63 (s, 2H), 8.33 - 8.41 (m, 3H), 8.22 – 8.26 (m, 2H), 8.17 (d, *J* = 9.8, 1H), 7.93 (d, *J* = 7.8, 1H), 7.72 (t, *J* = 7.9, 1H), 7.54 – 7.41 (m, 2H), 7.16 (d, *J* = 9.7, 1H), 5.45 (s, 2H), 4.12 (s, 2H), 2.77 (s, 2H), 0.65 (q, *J* = 6.5, 2H), 0.61 (q, *J* = 6.5, 2H).


3-(1-{3-[5-((1S,2S)-2-Aminomethylcyclopropylmethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile ("A16")



HPLC: Rt. = 2.29 min (method D), ESI: 465 (M+H);

¹H NMR (500 MHz, DMSO-d₆) δ [ppm] 8.62 (d, *J* = 7.4, 2H), 8.42 – 8.30 (m, 3H), 8.21-8.27 (m, 2H), 8.16 (d, *J* = 9.8, 1H), 7.92 (d, *J* = 7.8, 1H), 7.71 (t, *J* = 7.9, 1H), 7.44 – 7.51 (m, 2H), 7.15 (d, *J* = 9.8, 1H), 5.44 (s, 2H), 4.16 (dd, *J* = 6.5, 10.4, 1H), 4.00 (dd, *J* = 7.4, 10.5, 1H), 2.67 (d, *J* = 7.1, 2H), 1.26 (s, 1H), 1.05 (s, 1H), 0.69 – 0.57 (m, 2H).


3-(1-{3-[5-((1S,2S)-2-Dimethylaminomethylcyclopropylmethoxy)pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile ("A17")



HPLC: Rt. = 2.34 min (method D), ESI: 493 (M+H); the product is in the form of the formate salt;

¹H NMR (500 MHz, DMSO-d₆) δ [ppm] 8.62 (s, 2H), 8.37 (d, *J* = 10.0, 2H), 8.20-8.31 (m, 3H), 8.16 (d, *J* = 9.8, 1H), 7.92 (d, *J* = 7.8, 1H), 7.72 (t, *J* = 7.9, 1H), 7.46 – 7.52 (m, 2H), 7.15 (d, *J* = 9.7, 1H), 5.45 (s, 2H), 4.04 – 4.12 (m, 2H), 2.37 (dd, *J* = 6.1, 12.5, 1H), 2.25 (d, *J* = 4.0, 6H), 2.18 (dd, *J* = 7.2, 12.5, 1H), 1.12 (s, 1H), 0.95 (s, 1H), 0.69 – 0.58 (m, 1H), 0.49 (dt, *J* = 4.9, 9.7, 1H).

2-{3-[5-((1S,2S)-2-Aminomethylcyclopropylmethoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one ("A18")




HPLC: Rt. = 2.04 min (method C), ESI: 444 (M+H);

¹H NMR (500 MHz, DMSO-d₆) δ [ppm] 8.63 (s, 2H), 8.28 (s, 1H), 8.20 – 8.25 (m, 2H), 7.95 (b, 3H), 7.89 (s, 1H), 7.81 (d, *J* = 9.6, 1H), 7.53 – 7.38 (m, 2H), 7.05 (d, *J*

= 9.6, 1H), 5.33 (s, 2H), 4.21 (dd, $J = 6.3, 10.5$, 1H), 4.01 (dd, $J = 7.5, 10.5$, 1H), 2.83 – 2.71 (m, 2H), 1.36 (d, $J = 4.2$, 1H), 1.11 (s, 1H), 0.77 – 0.65 (m, 2H).

3-(1-(3-[5-((1S,2R)-2-Aminocyclopentyloxy)pyrimidin-2-yl]benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile ("A19")




HPLC: Rt. = 1.93 min (method C), ESI: 465 (M+H);

the product is in the form of the formate;

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.66 (s, 2H), 8.38 (d, $J = 8.1$, 2H), 8.28 (s, 1H), 8.27 – 8.19 (m, 2H), 8.17 (d, $J = 9.8$, 1H), 7.92 (d, $J = 7.7$, 1H), 7.72 (t, $J = 7.9$, 1H), 7.54 – 7.42 (m, 2H), 7.15 (d, $J = 9.7$, 1H), 5.44 (s, 2H), 4.84 – 4.72 (m, 1H), 3.43 (dd, $J = 7.8, 12.2$, 1H), 2.05 (dd, $J = 6.2, 11.6$, 1H), 1.98 – 1.72 (m, 3H), 1.68 – 1.51 (m, 2H).

2-(3-[5-((1S,2R)-2-Aminocyclopentyloxy)pyrimidin-2-yl]benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one ("A20")




HPLC: Rt. = 1.99 min (method C), ESI: 444 (M+H);

the product is in the form of the hydrochloride;

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.69 (s, 2H), 8.30 (s, 3H), 8.21 – 8.25 (m, 2H), 7.89 (s, 1H), 7.81 (d, $J = 9.6$, 1H), 7.54 – 7.40 (m, 2H), 7.05 (d, $J = 9.6$, 1H), 5.34 (s, 2H), 4.99 (d, $J = 2.5$, 1H), 3.70 (s, 1H), 2.17 – 2.02 (m, 2H), 1.86 (t, $J = 9.9$, 3H), 1.67 (d, $J = 9.1$, 1H).

Preparation of 2-(3-[5-(3-hydroxycyclopentyloxy)pyrimidin-2-yl]benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one ("A22")




100 mg (0.28 mmol) of 2-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one are dissolved in 6 ml of DMF, and 277 mg (0.83 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 33 mg (0.32 mmol) of 1,3-cyclopentanediol are added. The reaction mixture is shaken at room temperature for 15 min, and 196 mg (0.83 mmol) of di-*tert*-butyl azodicarboxylate are subsequently added. The reaction mixture was shaken at room temperature for 3 h, a further 277 mg (0.83 mmol) of polymer-bound triphenylphosphine (3mmol/g) and 196 mg (0.83 mmol) of di-*tert*-butyl azodicarboxylate were added, and the mixture was shaken at room temperature for 18 h. The reaction mixture is filtered off through kieselguhr with suction and washed with acetonitrile. The filtrate is evaporated and purified by means of preparative HPLC.

HPLC: Rt. = 2.46 min (method C), ESI: 445 (M+H);

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 8.57 (s, 2H), 8.28 (s, 1H), 8.21 (t, $J = 3.7$, 2H), 7.89 (s, 1H), 7.81 (d, $J = 9.6$, 1H), 7.53 – 7.37 (m, 2H), 7.05 (d, $J = 9.6$, 1H), 5.33 (s, 2H), 5.00 – 4.87 (m, 1H), 4.66 (dd, $J = 3.9$, 9.7, 1H), 4.18 – 4.10 (m, 1H), 3.87 (s, 3H), 2.39 (dt, $J = 6.9$, 14.0, 1H), 2.08 – 1.97 (m, 1H), 1.89 (dt, $J = 7.0$, 13.1, 1H), 1.80 – 1.54 (m, 3H).


The following is obtained analogously:

3-(1-(3-[5-(3-Hydroxycyclopentyloxy)pyrimidin-2-yl]benzyl)-6-oxo-1,6-dihydro-pyridazin-3-yl)benzonitrile ("A23")



HPLC: Rt. = 2.84 min (method C), ESI: 466 (M+H);

Preparation of 3-(1-{3-[5-(1-cyclopropylmethylpiperidin-4-ylmethoxy)pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile ("A24")



130 mg (0.185 mmol) of 3-(6-oxo-1-{3-[5-(piperidin-4-ylmethoxy)pyrimidin-2-yl]-benzyl}-1,6-dihydropyridazin-3-yl)benzonitrile (liberated from the hydrochloride by suspension in THF and extraction with 1N NaOH), 28 μ l (0.37 mmol) of cyclopropanecarboxaldehyde and 78 mg (0.37 mmol) of sodium triacetoxyborohydride are dissolved in 10 ml of THF, and 200 μ l of acetic acid are added. The reaction mixture is stirred at 40°C for 15 h. The reaction mixture is filtered and washed with THF. The filtrate is evaporated and purified by means of preparative HPLC.

HPLC: Rt. = 2.66 min (method B), ESI: 533 (M+H);

^1H NMR (500 MHz, DMSO- d_6) δ [ppm] 9.09 (b, 1H), 8.67 (s, 2H), 8.39 (d, J = 7.1, 2H), 8.22-8.26 (m, 2H), 8.18 (d, J = 9.8, 1H), 7.94 (d, J = 7.8, 1H), 7.73 (t, J = 7.9, 1H), 7.56 – 7.44 (m, 2H), 7.17 (d, J = 9.7, 1H), 5.46 (s, 2H), 4.13 (d, J = 6.0, 2H), 3.61 (d, J = 11.2, 2H), 3.05 – 2.91 (m, 4H), 2.16 – 1.75 (m, 3H), 1.59 (dd, J = 11.4, 24.4, 2H), 1.08 (s, 1H), 0.72 – 0.60 (m, 2H), 0.38 (q, J = 4.5, 2H).

Pharmacological data

Table 1 Met kinase inhibition (enzyme assay and/or cell assay)

Compound No.	IC ₅₀ (enzyme)	IC ₅₀ (cell)
"A1"	A	
"A2"	A	
"A3"	A	
"A4"	A	
"A5"	A	
"A6"	A	
"A7"	A	
"A8"	A	
"A11"	A	
"A13"	A	
"A13a"	A	
"A13b"	A	
"A13c"	A	
"A14"	A	
"A15"	A	
"A16"		
"A17"	A	
"A18"	A	
"A19"	A	
"A20"	A	
"A22"		
"A23"	A	
"A24"	A	

IC₅₀: 10 nM - 1 μ M = A 1 μ M - 10 μ M = B > 10 μ M = C

The following examples relate to medicaments:

Example A: Injection vials

A solution of 100 g of an active compound of the formula I according to Claim 1 and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active compound.

Example B: Suppositories

A mixture of 20 g of an active compound of the formula I according to Claim 1 with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.

Example C: Solution

A solution is prepared from 1 g of an active compound of the formula I according to Claim 1, 9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 l and sterilised by irradiation. This solution can be used in the form of eye drops.

Example D: Ointment

500 mg of an active compound of the formula I according to Claim 1 are mixed with 99.5 g of Vaseline under aseptic conditions.

Example E: Tablets

A mixture of 1 kg of active compound of the formula I according to Claim 1, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed in a conventional manner to give tablets in such a way that each tablet contains 10 mg of active compound.

Example F: Dragees

Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.

Example G: Capsules





2 kg of active compound of the formula I according to Claim 1 are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule contains 20 mg of the active compound.




Example H: Ampoules



A solution of 1 kg of active compound of the formula I according to Claim 1 in 60 l of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active compound.

SZABADALMI IGÉNYPONTOK

1. Vegyületek az alábbi csoportból megválasztva

No.	Név és/vagy szerkezet
"A1"	<p>(2S,3S)-2-amino-3-metoxi-N-[2-(2-{3-[3-(1-metil-1H-pirazol-4-il)-6-oxo-6H-piridazin-1-ilmetil]fenil}pirimidin-5-iloxi)etil]butiramid</p> 
"A2"	<p>N-[2-(2-{3-[3-(1-metil-1H-pirazol-4-il)-6-oxo-6H-piridazin-1-il-metil]fenil}pirimidin-5-iloxi)etil]-(2S,4R)-4-hidroxi-pirrolidin-2-karboxamid</p> 
"A3"	<p>N-[2-(2-{3-[3-(1-metil-1H-pirazol-4-il)-6-oxo-6H-piridazin-1-il-metil]fenil}pirimidin-5-iloxi)etil]-(S)-pirrolidin-2-karboxamid</p> 
"A4"	<p>N-[2-(2-{3-[3-(3-cianofenil)-6-oxo-6H-piridazin-1-ilmetil]-fenil}pirimidin-5-iloxi)etil]-(2S,4R)-4-hidroxi-pirrolidin-2-karboxamid ("A4")</p> 

No.	Név és/vagy szerkezet
"A5"	<p data-bbox="304 275 1378 360">N-[2-(2-(3-(3-(3-cianofenil)-6-oxo-6H-piridazin-1-ilmetil)-fenil)pirimidin-5-iloxi)etil]-(S)-pirrolidin-2-karboxamid ("A5")</p> 
"A6"	<p data-bbox="304 656 1378 741">(2S,3S)-2-amino-N-[2-(2-(3-(3-(3-cianofenil)-6-oxo-6H-piridazin-1-ilmetil)fenil)pirimidin-5-iloxi)etil]-3-metoxi-butiramid ("A6")</p> 
"A7"	<p data-bbox="304 1048 1362 1133">(S)-2-acetilamino-3-metil-N-[2-(2-(3-(3-(1-metil-1H-pirazol-4-il)-6-oxo-6H-piridazin-1-ilmetil)fenil)pirimidin-5-iloxi)-etil]butiramid</p> 
"A8"	<p data-bbox="304 1485 1378 1570">(S)-2-acetilamino-N-[2-(2-(3-(3-(3-cianofenil)-6-oxo-6H-piridazin-1-ilmetil)fenil)pirimidin-5-iloxi)etil]-3-metil-butiramid</p>
"A11"	<p data-bbox="304 1603 1267 1688">(S)-2-amino-5-(2-(3-(3-(1-metil-1H-pirazol-4-il)-6-oxo-6H-piridazin-1-ilmetil)fenil)pirimidin-5-iloxi)pentáasav</p>
"A13"	<p data-bbox="304 1722 1378 1807">2-(3-[5-(4-dimetilaminometilciklohexilmetoxi)pirimidin-2-il]benzil)-6-(1-metil-1H-pirazol-4-il)-2H-piridazin-3-on</p>
"A13a"	<p data-bbox="304 1841 1378 1926">2-(3-[5-(4-aminometilciklohexilmetoxi)pirimidin-2-il]-benzil)-6-(1-metil-1H-pirazol-4-il)-2H-piridazin-3-on</p>

No.	Név és/vagy szerkezet
"A13b"	3-(1-{3-[5-(4-aminometilciklohexilmetoxi)pirimidin-2-il]-benzil}-6-oxo-1,6-dihidropiridazin-3-il)benzonitril
"A13c"	3-(1-{3-[5-(2-aminometilciklopropilmetoxi)pirimidin-2-il]-benzil}-6-oxo-1,6-dihidropiridazin-3-il)benzonitril ("A13c") 
"A14"	2-{3-[5-(1-aminometilciklopropilmetoxi)pirimidin-2-il]-benzil}-6-(1-metil-1H-pirazol-4-il)-2H-piridazin-3-on
"A15"	3-(1-{3-[5-(1-aminometilciklopropilmetoxi)pirimidin-2-il]-benzil}-6-oxo-1,6-dihidropiridazin-3-il)benzonitril
"A16"	3-(1-{3-[5-((1S,2S)-2-aminometilciklopropilmetoxi)pirimidin-2-il]benzil}-6-oxo-1,6-dihidropiridazin-3-il)-benzonitril
"A17"	3-(1-{3-[5-((1S,2S)-2-dimetilaminometilciklopropilmetoxi)pirimidin-2-il]benzil}-6-oxo-1,6-dihidropiridazin-3-il)benzonitril
"A18"	2-{3-[5-((1S,2S)-2-aminometilciklopropilmetoxi)pirimidin-2-il]benzil}-6-(1-metil-1H-pirazol-4-il)-2H-piridazin-3-on
"A19"	3-(1-{3-[5-((1S,2R)-2-aminociklopentiloxi)pirimidin-2-il]-benzil}-6-oxo-1,6-dihidropiridazin-3-il)benzonitril 
"A20"	2-{3-[5-((1S,2R)-2-aminociklopentiloxi)pirimidin-2-il]benzil}-6-(1-metil-1H-pirazol-4-il)-2H-piridazin-3-on
"A22"	2-{3-[5-(3-hidroxiciklopentiloxi)pirimidin-2-il]benzil}-6-(1-metil-1H-pirazol-4-il)-2H-piridazin-3-on

No.	Név és/vagy szerkezet
"A23"	3-(1-{3-[5-(3-hidroxiciklopentiloxi)pirimidin-2-il]benzil}-6-oxo-1,6-dihidropiridazin-3-il)benzonitril
"A24"	3-(1-{3-[5-(1-ciklopropilmetilpiperidin-4-ilmetoxi)pirimidin-2-il]benzil}-6-oxo-1,6-dihidropiridazin-3-il)benzonitril

valamint ezek gyógyszerészetileg alkalmazható sói, tautomer és sztereoizomer formái, beleértve ezek tetszőleges arányú keverékeit.

2. Gyógyszerkészítmény, amely legalább egy, az 1. igénypont szerinti vegyületet és/vagy ennek gyógyszerészetileg alkalmazható sóját, tautomer és sztereoizomer formáját, beleértve ezek tetszőleges arányú keverékeit, tartalmazza adott esetben hordozóanyag és/vagy segédanyag mellett.

3. Az 1. igénypont szerinti vegyületek, valamint ezek gyógyszerészetileg alkalmazható sói, tautomer és sztereoizomer formái, beleértve ezek tetszőleges arányú keverékeit, alkalmazása betegségek kezelésére alkalmas gyógyszerkészítmények előállítására, ahol a kezelendő betegség szilárd tumor vagy a vér- és immunrendszer tumorja.

4. Gyógyszerkészítmény, amely legalább egy, az 1. igénypont szerinti vegyületet és/vagy ennek gyógyszerészetileg alkalmazható sóját, tautomer és sztereoizomer formáját, beleértve ezek tetszőleges arányú keverékeit, tartalmazza legalább egy további gyógyszerhatóanyag mellett.

5. Készlet (kit), amely elkülönített csomagokban tartalmaz

a) hatékony mennyiségben az 1. igénypont szerinti vegyületet és/vagy ennek gyógyszerészetileg alkalmazható sóját és sztereoizomer formáját, beleértve ezek tetszőleges arányú keverékeit, és

b) hatékony mennyiségben egy további gyógyszerhatóanyagot.